DILACOR XR
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
May 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DILACOR XR is an extended-release oral capsule small molecule approved in 1992 by AbbVie. The specific indication and mechanism of action are not documented in available data. This product represents a mature, legacy formulation in the market.
LOE Approaching
With LOE approaching and moderate competitive pressure (30th percentile), the brand team is likely in optimization and defense mode rather than growth mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DILACOR XR currently shows zero linked job openings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career growth on this product is limited; professionals should expect focus on market defense, customer retention, and potential transition roles rather than expansion opportunities.
Brand ManagerField Sales Representative
Worked on DILACOR XR at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.